Skip to main content

Bank of America Securities Keeps Their Sell Rating on ProKidney (PROK)

Tipranks - Tipranks - Fri Nov 14, 2025

Bank of America Securities analyst Jason Gerberry reiterated a Sell rating on ProKidney yesterday and set a price target of $1.00. The company’s shares closed yesterday at $2.68.

Meet Your ETF AI Analyst

According to TipRanks, Gerberry is a 5-star analyst with an average return of 10.6% and a 58.23% success rate. Gerberry covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals, Jazz Pharmaceuticals, and Alkermes.

The word on The Street in general, suggests a Hold analyst consensus rating for ProKidney with a $4.67 average price target.

See today’s best-performing stocks on TipRanks >>

Based on ProKidney’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $217 thousand and a GAAP net loss of $19.37 million. In comparison, last year the company had a GAAP net loss of $17.91 million

Read More on PROK:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).